신보조 화학요법과 트라스투주맙 병용 후 병리학적 완전관해는 인간 상피세포 성장인자 수용체 2 과발현 유방암에서 유리한 생존을 예측함: AGO 및 GBG 연구 그룹의 TECHNO 시험 결과

Untch 등(화,)이 이 문제를 연구했다.

www.synapsesocial.com/papers/69dd4bd7656f15f1fc101074 — DOI: https://doi.org/10.1200/jco.2010.31.4930

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer· 2010 · 527 citations
2. Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen· 2007 · 468 citations
3. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial· 2007 · 1,511 citations
4. Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.· 2009 · 554 citations
5. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer· 2007 · 356 citations